Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 411

Sort by

Sort Order Select

Journal Articles

How I incorporate novel agents into the treatment of classical Hodgkin lymphoma

Narendranath Epperla, Alex F. Herrera

Blood (2021) 138 (7): 520–530.

https://doi.org/10.1182/blood.2020007900

Published: 2021

Journal Articles

Mutational landscape of gray zone lymphoma

Blood (2021) 137 (13): 1765–1776.

https://doi.org/10.1182/blood.2020007507

Published: 2021

Includes: Supplemental data

Journal Articles

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Blood (2021) 137 (10): 1353–1364.

https://doi.org/10.1182/blood.2020006464

Published: 2021

Includes: Supplemental data

Journal Articles

Immune escape mechanisms for TCRLBCL

Wing C. Chan

Blood (2021) 137 (10): 1274–1276.

https://doi.org/10.1182/blood.2020008766

Published: 2021

Journal Articles

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Palmer, Barbara Pro, Reem Karmali, Eric Mou, Jeffrey Bearden, Gary Dillehay, Robert A. Bayer, Robert M. Eisner, Joan S. Chmiel, Kaitlyn O’Shea, Leo I. Gordon, Jane N. Winter

Blood (2021) 137 (10): 1318–1326.

https://doi.org/10.1182/blood.2020007400

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Kirsty Wienand, Atanas Kamburov, Gabriel K. Griffin, Pei-Hsuan Chen, Ana Lako, Robert A. Redd, Claire M. Cote, Matthew D. Ducar, Aaron R. Thorner, Scott J. Rodig, Gad Getz, Margaret A. Shipp

Blood (2019) 134 (26): 2369–2382.

https://doi.org/10.1182/blood.2019002067

Published: 2019

Includes: Supplemental data

Journal Articles

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Sanjay S. Patel, Jason L. Weirather, Mikel Lipschitz, Ana Lako, Pei-Hsuan Chen, Gabriel K. Griffin, Philippe Armand, Margaret A. Shipp, Scott J. Rodig

Blood (2019) 134 (23): 2059–2069.

https://doi.org/10.1182/blood.2019002206

Published: 2019

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Blood (2019) 134 (Supplement_1): 130.

https://doi.org/10.1182/blood-2019-126787

Published: 2019

Journal Articles

May Tigit (T cell Ig and ITIM domain) Expression be a New Target for Hodgkin Lymphoma?

Ombretta Annibali, Antonella Bianchi, Alba Grifoni, Valeria Tomarchio, Mariantonietta Tafuri, MD, Martina Verri, Giuseppe Avvisati, MD, Anna Crescenzi

Blood (2019) 134 (Supplement_1): 5235.

https://doi.org/10.1182/blood-2019-130794

Published: 2019

Journal Articles

A Complicated Neighborhood: Insights into the Hodgkin Lymphoma Microenvironment

Maher K. Gandhi, PhD

Blood (2019) 134 (Supplement_1): SCI-8.

https://doi.org/10.1182/blood-2019-121284

Published: 2019

Journal Articles

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Paul J Bröckelmann, MD, Annette Plütschow, Richard Greil, MD, Josée M Zijlstra, MD PhD, Timothy Illidge, MD PhD, Alexander Fosså, MD PhD, Julia Meissner, MD, Andreas Zimmermann, MD, Stephan Mathas, MD, Felicitas Thol, MD, Michael Fuchs, MD, Andreas Engert, MD, Christian Baues, MD

Blood (2019) 134 (Supplement_1): 1547.

https://doi.org/10.1182/blood-2019-124351

Published: 2019

Journal Articles

Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies

Philippe Armand, Pier Luigi Luigi Zinzani, MD, John Palcza, Jane Anne Healy, Akash Nahar, Patricia Marinello, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 1548.

https://doi.org/10.1182/blood-2019-127474

Published: 2019

Journal Articles

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Graca M. Dores, MD, Rochelle E. Curtis, MA, Nicole H. Dalal, BA, Martha S. Linet, MD MPH, Lindsay M. Morton, PhD

Blood (2019) 134 (Supplement_1): 4034.

https://doi.org/10.1182/blood-2019-124831

Published: 2019

Journal Articles

Baseline Metabolic Tumor Volume in 18FDG-PET-CT Scans in Classical Hodgkin Lymphoma Using Semi-Automatic Segmentation

Julia Driessen, BSc, Gerben J.C. Zwezerijnen, MD, Jakoba J Eertink, MSc, Marie José Kersten, MD PhD, Anton Hagenbeek, MD PhD, Otto S Hoekstra, MD PhD, Josée M Zijlstra, MD PhD, Ronald Boellaard, MSc, PhD

Blood (2019) 134 (Supplement_1): 4049.

https://doi.org/10.1182/blood-2019-125495

Published: 2019

Journal Articles

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Chadi Nabhan, MDMBA, FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 4057.

https://doi.org/10.1182/blood-2019-129632

Published: 2019

Journal Articles

Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse

Collin Chin, MBBS, Andrew Wirth, MBBS, MD FRACP, FRANZCR, David Ritchie, MD PhD, Michael Hofman, MBBS (Hons), FRACP, FAANMS, Michael MacManus, John F. Seymour, MBBS, PhD FRACP, Belinda Campbell, MBBS, MMed, FRANZCR, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 4044.

https://doi.org/10.1182/blood-2019-122716

Published: 2019

Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 4029.

https://doi.org/10.1182/blood-2019-123879

Published: 2019

Journal Articles

Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL)

Luis E Malpica Castillo, MD, Camila Peña, MD, Christine Rojas, MD, Pilar León, MD, Brady E. Beltrán, MD, Denisse A. Castro, MD, Yesenia M. Huerta- Collado, MD, Mimsy Quinones, MD, Sally Rose Paredes, MD, Henry Idrobo, MD, Ivan Perdomo, MD, Virginia Abello, MD, Lorena Fiad, MD, Victoria Otero, MD, Marialejandra Torres Viera, MD, Luis Villela M, Eduardo Sotomayor, MD, Jorge J Castillo, MD, Juan Carlos Ramos, MD BS

Blood (2019) 134 (Supplement_1): 4045.

https://doi.org/10.1182/blood-2019-122976

Published: 2019

Journal Articles

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL

Sairah Ahmed, MD, Julie Lisano, PharmD, Trevor Newhook, MS

Blood (2019) 134 (Supplement_1): 4054.

https://doi.org/10.1182/blood-2019-121523

Published: 2019

Journal Articles

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

Blood (2019) 134 (Supplement_1): 4026.

https://doi.org/10.1182/blood-2019-124116

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

How I incorporate novel agents into the treatment of classical Hodgkin lymphoma

Mutational landscape of gray zone lymphoma

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Immune escape mechanisms for TCRLBCL

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

May Tigit (T cell Ig and ITIM domain) Expression be a New Target for Hodgkin Lymphoma?

A Complicated Neighborhood: Insights into the Hodgkin Lymphoma Microenvironment

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Baseline Metabolic Tumor Volume in 18FDG-PET-CT Scans in Classical Hodgkin Lymphoma Using Semi-Automatic Segmentation

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL)

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only